You can buy or sell EYPT and other stocks, options, ETFs, and crypto commission-free!
EyePoint Pharmaceuticals, Inc. Common Stock, also called EyePoint Pharmaceuticals, is a biopharmaceutical company. Read More It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
52 Week High
52 Week Low
The Motley FoolMar 14
EYEPOINT PHARMACEUTICALS INC (EYPT) Q2 2019 Earnings Conference Call Transcript
EYEPOINT PHARMACEUTICALS INC (NASDAQ:EYPT) Q2 2019 Earnings Conference Call , 8:30 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good morning. My name is Amanda, and I will be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharma's Fiscal Period Ended December 31st, 2018 Financial Results Conference Call. There will be a question-and-answer session to follow at the completion of the prepared rema...
Stock Price, News, & Analysis for Eyepoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases. The company's lead product is ILUVIEN for the treatment of diabetic macular edema; and product candidate is YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis that is in the Phase III clinical trials. It also offers Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for...
-$0.14 per share
-$0.12 per share